Abbott to Release Metabolic Nutrition Formulas

  • Metabolic nutrition formulas previously on hold will be released free of charge to patients, in coordination with healthcare professionals based on need and on a case-by-case basis
  • The lots being released were not included in the February recall and are now being released at the request of the U.S. FDA
  • Patients, caregivers and healthcare professionals with questions should contact Abbott at +1-800-881-0876

At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas that were previously on hold following Abbott's recall of some powder infant formulas from its Sturgis, Mich. facility. The products have been tested and comply with all product release requirements before distribution. The lots being released were not included in the recall.

These products are used under the care of a healthcare professional and require a medical referral. Patients, caregivers and healthcare professionals in need of these products should contact Abbott at +1-800-881-0876 to provide necessary information. Abbott will work with metabolic centers and healthcare providers to fulfill requests based on need and on a case-by-case basis.

The metabolic products being released are:

  • Calcilo XD ®
  • Cyclinex ® -1 and 2
  • Glutarex ® -1 and 2
  • Hominex ® -1 and 2
  • I-Valex ® -1 and 2
  • Ketonex ® -1 and 2
  • Phenex ® -1 and 2
  • Pro-Phree ®
  • Propimex ® -1 and 2
  • ProViMin ®
  • Tyrex ® -1 and 2

The specialty product being released is:

  • Similac ® PM 60/40

Similac ® , Alimentum ® and EleCare ® powder formulas that were voluntarily recalled in February are not included in this product release.

Abbott has limited inventory of these products. New product is not currently being manufactured. Abbott has implemented corrective actions and is working with the FDA to address the situation before resuming operations at the Sturgis facility. Once Abbott resumes production, it will take at least six to eight weeks for product to be available for distribution.

No Link Between Sturgis Facility and Reported Cases
On Feb. 17, 2022 , Abbott issued a voluntary recall of some powder infant formula products manufactured at its Sturgis facility. The recall did not include any of Abbott's metabolic nutrition formulas , and included only a single batch of Similac PM 60/40. During the investigation, the metabolic nutrition formulas and all other batches of Similac PM 60/40 were placed on hold.

Abbott tests products prior to distribution, and no Abbott formula distributed to consumers tested positive for Cronobacter sakazakii or Salmonella . All finished product testing by Abbott and the FDA during the inspection of the facility likewise came back negative for Cronobacter sakazakii and/or Salmonella . No Salmonella was found at the Sturgis facility during the investigation. The Cronobacter sakazakii that was found in environmental testing during the investigation was in non-product contact areas of the facility and has not been linked to any known infant illness.

A thorough review of all available data indicates that the infant formula produced at our Sturgis facility is not likely the source of infection in the reported cases and that there was not an outbreak caused by products from the facility.

"We know this situation has worsened the industry-wide infant formula supply shortage and we regret the anxiety and stress this is causing," said Joe Manning , executive vice president, nutritional products, Abbott. "Abbott is committed to working with the FDA to address this situation so we can resume operations at this facility and continue serving the nutritional needs of people who rely on our infant and specialty formulas."

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

Cision View original content: https://www.prnewswire.com/news-releases/abbott-to-release-metabolic-nutrition-formulas-301536608.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×